Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $472.78 Average PT from Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has earned a consensus recommendation of “Moderate Buy” from the twenty-six analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $471.9587.

Several analysts recently commented on the company. Raymond James Financial reaffirmed an “outperform” rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Oppenheimer assumed coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $510.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Canaccord Genuity Group raised their target price on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Finally, Wells Fargo & Company raised their target price on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a report on Friday.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 beat driven by Amvuttra — Alnylam reported Q1 EPS of $1.99 and revenue of $1.17B, topping estimates; Amvuttra sales surged ~187% and helped drive 96% year‑over‑year revenue growth. Read More.
• Positive Sentiment: Brokerage support — Several brokerages continue to rate ALNY favorably (consensus around “moderate buy” and H.C. Wainwright remains a buy), which supports upside sentiment over the medium term. Read More.
• Neutral Sentiment: Mixed analyst target moves — Wells Fargo nudged its target slightly higher but kept an “equal weight” stance; RBC trimmed its target marginally but maintains an “outperform” view (still implying sizeable upside). These are tweaks rather than directional shifts. Read More. Read More.
• Neutral Sentiment: Investor materials and commentary available — Full earnings slide deck and call transcript were published (useful for modeling product-level trends and guidance; contributes to re‑rating discussions). Read More.
• Negative Sentiment: Risks and product headwinds — The quarter showed declines in collaborator revenue and Onpattro sales that offset some gains; an outside review highlighted a new regulatory risk and warned the stock could carry a higher risk of significant losses, which likely pressured sentiment. Read More.

Insider Activity

In related news, EVP Jeffrey V. Poulton sold 2,206 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $722,795.90. Following the sale, the executive vice president directly owned 64,273 shares of the company’s stock, valued at $21,059,048.45. This trade represents a 3.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Tolga Tanguler sold 1,598 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $523,584.70. Following the sale, the executive vice president directly owned 36,606 shares in the company, valued at approximately $11,993,955.90. This trade represents a 4.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 38,656 shares of company stock valued at $12,370,696 over the last 90 days. Company insiders own 0.86% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors have recently bought and sold shares of ALNY. Groupama Asset Managment grew its holdings in Alnylam Pharmaceuticals by 160.4% in the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after purchasing an additional 2,483,697 shares during the period. Norges Bank acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $895,816,000. Arrowstreet Capital Limited Partnership grew its holdings in Alnylam Pharmaceuticals by 698.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after purchasing an additional 1,185,909 shares during the period. Qube Research & Technologies Ltd acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $369,943,000. Finally, AQR Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 295.2% in the third quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock valued at $336,009,000 after purchasing an additional 555,759 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 4.3%

Shares of NASDAQ:ALNY opened at $296.11 on Friday. Alnylam Pharmaceuticals has a 52-week low of $245.96 and a 52-week high of $495.55. The stock has a market cap of $39.51 billion, a price-to-earnings ratio of 173.16 and a beta of 0.39. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The business has a 50-day moving average price of $320.11 and a 200-day moving average price of $377.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $1.09. The firm had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 118.63% and a net margin of 11.72%.The company’s revenue for the quarter was up 96.4% compared to the same quarter last year. During the same period last year, the business posted ($0.44) earnings per share. Equities analysts predict that Alnylam Pharmaceuticals will post 6.75 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.